Tear lipocalin: Evidence for a scavenging function to remove lipids from the human corneal surface

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 10, 2005, Pages 3589-3596

  Gasymov, Oktay K ^a   Abduragimov, Adil R ^a   Prasher, Pawan ^a   Yusifov, Taleh N ^a   Glasgow, Ben J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID BINDING PROTEIN; LIPOCALIN; LIPOCALIN 1; PHOSPHOLIPID; UNCLASSIFIED DRUG; 16 (9 ANTHROYLOXY)PALMITIC ACID; 16-(9-ANTHROYLOXY)PALMITIC ACID; CARRIER PROTEIN; CYSTEINE PROTEINASE INHIBITOR; EYE PROTEIN; FLUORESCENT DYE; PALMITIC ACID DERIVATIVE; PHOSPHATIDYLCHOLINE; TEAR PROTEINS;

ARTICLE; CORNEA EPITHELIUM; EVISCERATION; GEL PERMEATION CHROMATOGRAPHY; GOBLET CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; ION EXCHANGE CHROMATOGRAPHY; LACRIMAL FLUID; LIPID COMPOSITION; LIPID STORAGE; LUBRICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCAVENGING SYSTEM; SPECTROFLUOROMETRY; TEAR FILM; WETTABILITY; CHEMISTRY; CORNEA; FLUORESCENCE MICROSCOPY; GEL CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

CARRIER PROTEINS; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; CORNEA; CYSTEINE PROTEINASE INHIBITORS; EYE PROTEINS; FLUORESCENT DYES; HUMANS; MICROSCOPY, FLUORESCENCE; PALMITIC ACIDS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; SPECTROMETRY, FLUORESCENCE; TEARS;

EID: 32944482603     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0569     Document Type: Article

References (31)

1. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78:379-388.
2. Dartt DA. Control of mucin production by ocular surface epithelial cells. Exp Eye Res. 2004;78:173-185.
3. Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. Exp Eye Res. 1971;11:239-250.
4. Sharma A. Energetics of corneal epithelial cell-ocular mucus-tear film interactions: some surface-chemical pathways of corneal defense. Biophys Chem. 1993;47:87-99.
5. Doane MG. Abnormalities of the structure of the superficial lipid layer on the in vivo dry-eye tear film. Adv Exp Med Biol. 1994;350:489-493.
6. Golding TR, Bruce AS, Mainstone JC. Relationship between tearmeniscus parameters and tear-film breakup. Cornea. 1997;16:649-661.
7. Tseng SC, Zhang SH. Interaction between rose bengal and different protein components. Cornea. 1995;14:427-435.
8. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984;102:1049-1051.
9. Thoft RA, Friend J, Kinoshita S, Nikolic L, Foster CS. Ocular cicatricial pemphigoid associated with hyperproliferation of the conjunctival epithelium. Am J Ophthalmol. 1984;98:37-42.
10. Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci. 2003;44:2487-2495.
11. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982;89:1173-1180.
12. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004;23:272-285.
13. Dursun D, Monroy D, Knighton R, et al. The effects of experimental tear film removal on corneal surface regularity and barrier function. Ophthalmology. 2000;107:1754-1760.
14. Fullard RJ, Kissner DM. Purification of the isoforms of tear specific prealbumin. Curr Eye Res. 1991;10:613-628.
15. Glasgow BJ, Abduragimov AR, Farahbakhsh ZT, Faull KF, Hubbell WL. Tear lipocalins bind a broad array of lipid ligands. Curr Eye Res. 1995;14:363-372.
16. Abduragimov AR, Gasymov OK, Yusifov TN, Glasgow BJ. Functional cavity dimensions of tear lipocalin. Curr Eye Res. 2000;21:824-832.
17. Glasgow BJ, Marshall G, Gasymov OK, Abduragimov AR, Yusifov TN, Knobler CM. Tear lipocalins: potential lipid scavengers for the corneal surface. Invest Ophthalmol Vis Sci. 1999;40:3100-3107.
18. Gasymov OK, Abduragimov AR, Yusifov TN, Glasgow BJ. Site-directed tryptophan fluorescence reveals the solution structure of tear lipocalin: evidence for features that confer promiscuity in ligand binding. Biochemistry. 2001;40:14754-14762.
19. Breustedt DA, Korndorfer IP, Redl B, Skerra A. The 1.8-Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem. 2005;280:484-493.
20. Glasgow BJ. Tissue expression of lipocalins in human lacrimal and von Ebner's glands: colocalization with lysozyme. Graefes Arch Clin Exp Ophthalmol. 1995;233:513-522.
21. Lim WH, Lawrence MJ. Aggregation behavior of mixtures of phosphatidylcholine and polyoxyethylene sorbitan monoesters in aqueous solution. Phys Chem Chem Phys. 2004;6:1380-1387.
22. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. 5th ed. New York: John Wiley & Sons; 1991.
23. Gasymov OK, Abduragimov AR, Yusifov TN, Glasgow BJ. Binding studies of tear lipocalin: the role of the conserved tryptophan in maintaining structure, stability and ligand affinity. Biochim Biophys Acta. 1999;1433:307-320.
24. Van Haeringen NJ. Clinical biochemistry of tears. Surv Ophthalmol. 1981;26:84-96.
25. Holly FJ. Formation and rupture of the tear film. Exp Eye Res. 1973;15:515-525.
26. Fullard RJ, Wilson GS. Investigation of sloughed corneal epithelial cells collected by non-invasive irrigation of the corneal surface. Curr Eye Res. 1986;5:847-856.
27. Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol. 2003;231:1-49.
28. Caffery BE, Josephson JE. Corneal staining after sequential instillations of fluorescein over 30 days. Optom Vis Sci. 1991;68:467-469.
29. Yamada M, Mochizuki H, Kawai M, Tsubota K, Bryce TJ. Decreased tear lipocalin concentration in patients with meibomian gland dysfunction. Br J Ophthalmol. 2005;89:803-805.
30. Janssen PT, van Bijsterveld OP. Tear fluid proteins in Sjogren's syndrome. Scand J Rheumatol Suppl. 1986;61:224-227.
31. Schoenwald RD, Vidvauns S, Wurster DE, Barfknecht CF. Tear film stability of protein extracts from dry eye patients administered a sigma agonist. J Ocul Pharmacol Ther. 1997;13:151-161.